Skip navigation



Medherant Wins Excellence in Science & Technology Award

Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwickshire which have achieved success for themselves, their staff and their customers. More »
17 November 2017

Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell Types

Elpis BioMed Ltd, a University of Cambridge spin-out, applying its disruptive and proprietary “direct cell reprogramming” platform to produce pure, mature and highly consistent batches of human cell types for research, toxicology and drug development, has announced today that it has raised funds to bring its human cell products and services to market. Backed by a world-class investor team, led by industry expert Jonathan Milner, with co-investments from Darrin Disley, Weslie Janeway and Nikolaus Starzacher. The funds will be used to grow the Company’s catalogue of off-the-shelf human cell type products and expand its service offerings, marking its first step towards more complex products, including human organ-on-chip models, and cell-based therapies. More »
16 November 2017

ON Helix is Evolving

One Nucleus is delighted to announce the evolution of our Cambridge centrepiece conference, ON Helix. More »
15 November 2017

Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization

Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint in the U.K., and further supports the growth of Quotient’s Translational Pharmaceutics® platform, following the acquisitions of SeaView Research and QS Pharma in February 2017. More »
14 November 2017

Horizon Discovery’s Dharmacon Introduces Edit-R CRISPRa Reagent Platform for Genome-Wide CRISPR Activation

Horizon Discovery (LSE: HZD) (“Horizon” or the “Company”), a global leader in gene editing and gene modulation technologies, today announced the launch of its reagent platform for CRISPR activation (CRISPRa) from its recently acquired Dharmacon™ business. This is the latest addition to the Company’s market-leading Edit-R™ portfolio for CRISPR-Cas9 genome engineering. More »
14 November 2017

Bobby Deal - International GameChanger of the Year, 2017

This award was presented to Bobby Deal, Managing Director of GRS by ACQ5. "It is fantastic to obtain this recognition" said Bobby Deal, Managing Director of GRS, "especially since my objective was for GRS to be a GameChanger within the global life science sector and even more so for our niche area of regulatory affairs and quality compliance." More »
13 November 2017

Phenotypic Screening and Target Deconvolution: A Perfect Match

The phenotypic-based screening approach to drug discovery is an efficient strategy to identify promising small molecule hits by looking at the effect, or phenotype, that they induce in disease-relevant cells or tissues. More »
13 November 2017

In Search of a Disease-Modifying Agent for Parkinson’s Disease: A Discovery Story

Parkinson’s disease afflicts an estimated 6.3 million people globally, and there is currently no disease-modifying therapy that halts the progression of the disease. More »
13 November 2017

SYGNIS AG Partners with Abingdon Health to Provide Full Service Custom Lateral Flow Assay Design and Supply

SYGNIS AG, under the Innova Biosciences (Innova) brand name, a specialist provider of bioconjugation products and services, today announced it has established a partnership with Abingdon Health Ltd (“Abingdon”), which will enable Innova to provide its customers with full lateral flow assay development services as well as establishing Innova as the preferred colloidal gold supplier to Abingdon. More »
13 November 2017

Quotient Sciences Launches as the New Global Identity for Quotient Clinical

Quotient Clinical, the drug development services organization, announces its renaming to Quotient Sciences, following the acquisitions of Co-Formulate, QS Pharma and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers. More »
10 November 2017

<< Previous   Page 1 of 31   Next >>